Lanxess Invests €40 Million in 2 Projects at Krefeld-Uerdingen Site

Laying the foundation stone (from left to right): Hubert Fink, head of the...
Laying the foundation stone (from left to right): Hubert Fink, head of the Lanxess business unit Basic Chemicals; Werner Breuers, member of the board of management of the Lanxess AG; construction manager Alexander Kerns; and Gregor Kathstede, mayor of Krefeld.

Lanxess has announced a €40 million investment in two projects at its Krefeld-Uerdingen, Germany site.The company is building a production plant for the formalin needed to make trimethylolpropane (TMP). The applications of this trivalent alcohol include numerous products used in the furniture, construction and automotive industries. In addition to the plant itself, new formalin and methanol tanks will also be built on a total area of 1,000 m2 and is due to start up at the end of 2011.

In addition, the company said it is responding to strong global demand for menthol by investing in the expansion of its existing menthol production facilities. Synthetic menthol is a key component of numerous aromas and pharmaceutical products. Lanxess - in collaboration with Symrise - is the world's leading manufacturer of synthetic menthol and thymol. Initial planning work on the expansion of the hydrogenation facility is already under way, and the project is due to be completed during the first half of 2012.

Company

Logo:

LANXESS Deutschland GmbH

Kennedyplatz 1
50569 Köln
Germany

Company contact







Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.